Von Willebrand disease

Obstetrical and Gynecological Survey

Volumn 61, Issue 2, 2006, Pages 136-145

  James, Andra H ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXYTOCIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING DISORDER; CHILDBIRTH; CIRCULATION; DRUG INDUCED DISEASE; ENDOMETRIOSIS; ENDOTHELIUM INJURY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HEMATOMA; HUMAN; HYPONATREMIA; HYSTERECTOMY; MENORRHAGIA; MENSTRUATION; OVARY CYST; POSTPARTUM HEMORRHAGE; PREGNANCY; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; SURGICAL TECHNIQUE; THROMBOCYTE FUNCTION; VAGINAL DELIVERY; VON WILLEBRAND DISEASE; VULVA TUMOR;

ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; LEIOMYOMA; MENORRHAGIA; OVARIAN CYSTS; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; VON WILLEBRAND DISEASE;

EID: 33644834437     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000197818.94002.91     Document Type: Review

References (112)

1. von Willebrand E, Jurgens R. Dtsch Arch Klin Med 1933;175:453-483.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
3. Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia 1999;5:223-231; discussion 222.
4. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994;71:520-525.
5. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174.
6. Biron C, Mahieu B, Rochette A, et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999;134:605-609.
7. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459.
8. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993;123:893-898.
9. Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004;10:158-161.
10. Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74:784-790.
11. Greer IA, Lowe GD, Walker JJ, et al. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. BJOG 1991;98:909-918.
12. Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999;5:313-317.
13. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000;111:1236-1239.
14. Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000;6:643-648.
15. Kirtava A, Drews C, Lally C, et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003;9:292-297.
16. Perry JJ, Alving BM. von Willebrand's disease. Am Fam Physician 1990;41:219-224.
17. Woods AI, Meschengieser SS, Blanco AN, et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease. Haematologica 2001;86:420-427.
18. Federici A. Diagnosis of von Willebrand disease. Haemophilia 1998;4:654-660.
19. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973;238:1-159.
20. Kadir RA, Economides DL, Sabin CA, et al. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999;5:40-48.
21. Goodman-Gruen D, Hollenbach K. The Prevalence of von Willebrand disease in women with abnormal uterine bleeding. J Womens Health Gend Based Med 2001;10:677-680.
22. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97:630-636.
23. Edlund M, Blomback M, von Schoultz B, et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996;53:234-238.
24. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485-489.
25. Woo YL, White B, Corbally R, et al. von Willebrand's disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002;13:89-93.
26. Philipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003;1:477-484.
27. James AH, Lukes AS, Brancazio LR, et al. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. Am J Obstet Gynecol 2004;191:449-455.
28. Management of Anovulatory Bleeding. American College of Obstetricians and Gynecologists, 2000:1-12.
29. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004;190:1216-1223.
30. Miller CH, Dilley AB, Drews C, et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002;87:1082-1083.
31. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003;1:2191-2197.
32. Miller CH, Dilley A, Richardson L, et al. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. Am J Hematol 2001;67:125-129.
33. Keightley AM, Lam YM, Brady JN, et al. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999;93:4277-4283.
34. Gralnick HR, McKeown LP, Wilson OM, et al. von Willebrand factor release induced by endotoxin. J Lab Clin Med 1989;113:118-122.
35. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 1993;70:380-385.
36. Ruggeri ZM, Ware J. von Willebrand factor. Faseb J 1993;7:308-316.
37. Jennings I, Kitchen S, Woods TA, et al. Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme. Haemophilia 1998;4:739-746.
38. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552.
39. Rodgers RP. Bleeding time tables. A tabular summary of pertinent literature. Semin Thromb Hemost 1990;16:21-138.
40. Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998;133:134-139.
41. Lehman CM, Blaylock RC, Alexander DP, et al. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001;47:1204-1211.
42. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744.
43. Francis J. Platelet function analyzer (PFA)-100. In: Michelson A, ed. Platelets. New York: Academic Press, 2002:325-345.
44. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331.
45. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
46. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001;7:170-179.
47. James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol 2004;104:381-388.
48. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971;110:713-720.
49. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77:13-19.
50. Rivera R, Almonte H, Arreola M, et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 1983;27:311-327.
51. Effects of contraceptives on hemoglobin and ferritin. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Contraception 1998;58:262-273.
52. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimateethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-920.
53. Sicat BL. Ortho Evra, a new contraceptive patch. Pharmacotherapy 2003;23:472-480.
54. Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;111:1425-1428.
55. Leissinger C, Becton D, Cornell C Jr, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001;7:258-266.
56. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002;8:787-793.
57. Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998;4:63-65.
58. Abnormal uterine bleeding. In: Stenchever M, Droegemueller W, Herbst A, eds. Comprehensive Gynecology. Philadelphia: Mosby, 2001:1079-1097.
59. Siegel JE, Kouides PA. Menorrhagia from a haematologist's point of view. Part II: management. Haemophilia 2002;8:339-347.
60. Humate-P: Prescribing Information, Antihemophilic Factor/ von Willebrand Factor Complex (Human) Dried, Pasteurized. Aventis Behring, 2003:1-2.
61. Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004;10:218-231.
62. Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia - experience with seven cases. Haemophilia 2004;10:477-482.
63. Bain C, Cooper KG, Parkin DE. Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstet Gynecol 2002;99:983-987.
64. Boujida VH, Philipsen T, Pelle J, et al. Five-year follow-up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstet Gynecol 2002;99:988-992.
65. Comino R, Torrejon R. Hysterectomy after endometrial ablation-resection. J Am Assoc Gynecol Laparosc 2004;11:495-499.
66. Phillips G, Chien PF, Garry R. Risk of hysterectomy after 1000 consecutive endometrial laser ablations. BJOG 1998; 105:897-903.
67. Dutton C, Ackerson L, Phelps-Sandall B. Outcomes after rollerball endometrial ablation for menorrhagia. Obstet Gynecol 2001;98:35-39.
68. Unger JB, Meeks GR. Hysterectomy after endometrial ablation. Am J Obstet Gynecol 1996;175:1432-1436; discussion 1436-1437.
69. Jarvis RR, Olsen ME. Type I von Willebrand's disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002;99:887-888.
70. Bottini E, Pareti FI, Mari D, et al. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reports. Haematologica 1991;76:431-433.
71. Meschengieser SS, Alberto MF, Salviu J, et al. Recurrent haemoperitoneum in a mild von Willebrand's disease combined with a storage pool deficit. Blood Coagul Fibrinolysis 2001;12:207-209.
72. Gomez A, Lucia JF, Perella M, et al. Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease. Haemophilia 1998;4:60-62.
73. Ghosh K, Mohanty D, Pathare AV, et al. Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive. Haemophilia 1998;4:767-768.
74. Endometriosis and adenomyosis. In: Stenchever M, et al., eds. Comprehensive Gynecology. Philadelphia: Mosby; 2001:531-564.
75. Vercellini P, De Giorgi O, Aimi G, et al. Menstrual characteristics in women with and without endometriosis. Obstet Gynecol 1997;90:264-268.
76. Krause M, Aygroren-Pursun E, Ehrenforth S, et al. Inherited and acquired coagulation disorders in women with menorrhagia. Thromb Haemost 2001;86S:P1137.
77. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. BJOG 1998; 105:314-321.
78. Kadir RA. Women and inherited bleeding disorders: pregnancy and delivery. Semin Hematol 1999;36:28-35.
79. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16:153-168.
80. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003;29:125-130.
81. Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol 2001;14:381-399.
82. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-1919.
83. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998;53:450-455.
84. Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970;49:241-242.
85. Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl 1982;5:214-220.
86. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238-240.
87. Astedt B, Nilsson IM. Recurrent abruptio placentae treated with the fibrinolytic inhibitor tranexamic acid. BMJ 1978;1:756-757.
88. Svanberg L, Astedt B, Nilsson IM. Abruptio placentae - treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980;59:127-130.
89. Storm O, Weber J. [Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy.] Ugeskr Laeger 1976; 138:1781-1782.
90. Sundqvist SB, Nilsson IM, Svanberg L, et al. Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia. Scand J Haematol 1981;27:159-164.
91. Howorka E, Olasinski R, Wyrzykiewicz T. [Effect of EACA administered to female rabbits during pregnancy on the fetuses.] Patol Pol 1970;21:311-314.
92. Kassam SH, Hadi HA, Fadel HE, et al. Sickle-cell-induced hematuria in pregnancy. The current diagnostic and therapeutic approach. J Reprod Med 1984;29:117-121.
93. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997;315:32-34.
94. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:1708-1712.
95. Chediak JR, Alban GM, Maxey B. von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986;155:618-624.
96. Burlingame J, McGaraghan A, Kilpatrick S, et al. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. Am J Obstet Gynecol 2001;184:229-230.
97. Caliezi C, Tsakiris DA, Behringer H, et al. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998;4:845-849.
98. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694.
99. Stedeford JC, Pittman JA. Von Willebrand's disease and neuroaxial anaesthesia. Anaesthesia 2000;55:1228-1229.
100. Stimate (Desmopressin acetate) Nasal Spray, 1.5 mg.mL, Prescribing Information. Aventis Behring, 2002:1-2.
101. Nilsson IM, Mikaelsson M, Vilhardt H. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Scand J Haematol 1982;29:70-74.
102. Gardella C, Taylor M, Benedetti T, et al. The effect of sequential use of vacuum and forceps for assisted vaginal delivery on neonatal and maternal outcomes. Am J Obstet Gynecol 2001;185:896-902.
103. Edwards A, Ellwood DA. Ultrasonographic evaluation of the postpartum uterus. Ultrasound Obstet Gynecol 2000;16:640-643.
104. Marchant S, Alexander J, Garcia J, et al. A survey of women's experiences of vaginal loss from 24 hours to three months after childbirth (the BLiPP study). Midwifery 1999; 15:72-81.
105. Visness CM, Kennedy KI, Ramos R. The duration and character of postpartum bleeding among breast-feeding women. Obstet Gynecol 1997;89:159-163.
106. Dahlman T, Hellgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985;20:37-44.
107. Lee CY, Madrazo B, Drukker BH. Ultrasonic evaluation of the postpartum uterus in the management of postpartum bleeding. Obstet Gynecol 1981;58:227-232.
108. Hoveyda F, MacKenzie IZ. Secondary postpartum haemorrhage: incidence, morbidity and current management. BJOG 2001;108:927-930.
109. Ramsahoye B, Davies S, Dasani H, et al. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995;1:140-144.
110. Roque H, Funai E, Lockwood CJ. von Willebrand disease and pregnancy. J Matern Fetal Med 2000;9:257-266.
111. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-219.
112. Conti M, Mari D, Conti E, et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986;68:282-285.